Interventions for Tuberculosis Control and Elimination 2002

1109. Lucchesi M. L’éthionamide activité, résistance, résistance croisée. New York:
Proceedings of the 20th Conference of IUATLD, 1969; 58-60.
1110. Franz H, Urbanczik R, Stoll K, Müller U. Prothionamid-Blutspiegel nach oraler
Verabreichung von Prothionamid allein oder kombiniert mit Isoniazid und/oder
mit Diamino-Difenylsulfon. Prax Pneumol 1974; 28: 605-12.
1111. Cooperative Study Unit on Chemotherapy of Tuberculosis of the National
Sanatoria in Japan. Comparison of the clinical usefulness of ethionamide and
prothionamide in initial treatment of tuberculosis: tenth series of controlled trials.
Tubercle 1968; 49: 281-90.
1112. Brouet G, Marche J, Rist N, Chevallier J, LeMeur G. Observations on the antituberculous
effectiveness of alpha-ethyl-thiosonicotinamide in tuberculosis in
humans. Am Rev Respir Dis 1959; 79: 6-18.
1113. Lees AW. Toxicity in newly diagnosed cases of pulmonary tuberculosis treated
with ethionamide. Am Rev Respir Dis 1963; 88: 347-54.
1114. Pernod J.
39-42.
Hepatic tolerance of ethionamide. Am Rev Respir Dis 1965; 92:
1115. Phillips S, Trevathan R. Serum glutamic oxaloacetic transaminase elevation and
possible hepatotoxicity accompanying the administration of ethionamide.
Rev Respir Dis 1962; 86: 268-9.
Am
1116. Phillips S, Tashman H.
896-8.
Ethionamide jaundice. Am Rev Respir Dis 1963; 87:
1117. Conn HO, Binder HJ, Orr HD.
Dis 1964; 90: 542-52.
Ethionamide-induced hepatitis. Am Rev Respir
1118. Gupta DK. Acceptability of thioamides II. prothionamide. J Postgraduate
Medicine 1977; 23: 181-5.
1119. Research Committee of the British Tuberculosis Association. A comparison of
the toxicity of prothionamide and ethionamide. Tubercle 1968; 49: 125-34.
1120. Schütz I, Bartmann K, Radenbach KL, Siegler W. Vergleich der Verträglichkeit
von Protionamid und Ethionamid im Doppelblindversuch.
Tuberkul Lungenkrankheiten 1969; 140: 296-303.
Klin Erforsch
1121. O’Brien RJ, Nunn PP. The need for new drugs against tuberculosis. Obstacles,
opportunities, and next steps. Am J Respir Crit Care Med 2001; 162: 1055-8.
1122. Jones PB, Parrish NM, Houston TA, Stapon A, Bansal NP, Dick JD,
Townsend CA.
43: 3304-14.
A new class of antituberculosis agents. J Med Chem 2000;
1123. Kasik JE.
91: 117-9.
The nature of mycobacterial penicillinase. Am Rev Respir Dis 1965;
1124. Segura C, Salvadó M, Collado I, Chaves J, Coira A. Contribution of β-lactamases
to β-lactam susceptibilities of susceptible and multidrug-resistant
Mycobacterium tuberculosis clinical isolates.
1998; 42: 1524-6.
Antimicrob Agents Chemother
244